Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

Completed · Phase 2

Conditions studied: Hypogonadism

In brief

Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.

Key facts

Study ID

NCT01323140

Run by

Watson Pharmaceuticals

People needed

40

Starts

2011-04-01

Expected to finish

2011-07-01

Last updated by the study team

2013-01-01

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male, 18 - 65 years of age;
• Documented testosterone deficiency;
• BMI 18 to 33.

You may not qualify if…

• Evidence of prostate cancer and benign prostate hyperplasia;
• Taking medications that interfere testosterone metabolism;
• History of alcohol or drug substance abuse;
• Abnormal ECG;
• Allergic to transdermal products;
• Skin condition that interfere transdermal system application and assessment

Where it is running

• Watson Investigational Site — Fort Meyers, Florida, United States
• Watson Investigational Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.